Summary
2.95 0.07(2.26%)07/05/2024
Pyxis Oncology Inc. (PYXS)
Pyxis Oncology Inc. (PYXS)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| 2.26 | 44.95 | 79.55 | 101.27 | 29.51 | 105.19 | 0.00 | -87.50 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 2.95 | |
| Open | 2.88 | |
| High | 2.98 | |
| Low | 2.81 | |
| Volume | 327,240 | |
| Change | 0.07 | |
| Change % | 2.26 | |
| Avg Volume (20 Days) | 387,838 | |
| Volume/Avg Volume (20 Days) Ratio | 0.84 | |
| 52 Week Range | 1.35 - 6.92 | |
| Price vs 52 Week High | -57.44% | |
| Price vs 52 Week Low | 118.15% | |
| Range | 0.64 | |
| Gap Up/Down | -0.03 | |
Fundamentals | ||
| Market Capitalization (Mln) | 171 | |
| EBIDTA | 0 | |
| PE Ratio | 0.0000 | |
| PEG Ratio | 0.0000 | |
| WallStreet Target Price | 21.25 | |
| Book Value | 0.0000 | |
| Earnings Per Share | -45.5880 | |
| EPS Estimate Current Quarter | -6.7800 | |
| EPS Estimate Next Quarter | -0.3400 | |
| EPS Estimate Current Year | -4.4000 | |
| EPS Estimate Next Year | -2.5300 | |
| Diluted EPS (TTM) | -45.5880 | |
| Revenues | ||
| Profit Marging | 0.0000 | |
| Operating Marging (TTM) | 0.0000 | |
| Return on asset (TTM) | 0.0000 | |
| Return on equity (TTM) | 0.0000 | |
| Revenue TTM | 0 | |
| Revenue per share TTM | 0.0000 | |
| Quarterly Revenue Growth (YOY) | 0.0000 | |
| Quarterly Earnings Growth (YOY) | 0.0000 | |
| Gross Profit (TTM) | 0 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 0.0000 | |
| Forward PE | 0.0000 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 0.0000 | |
| Revenue Enterprise Value | 0.0000 | |
| EBITDA Enterprise Value | 0.0000 | |
| Shares | ||
| Shares Outstanding | 32,763,900 | |
| Shares Float | 21,946,035 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.00 | |
| Insider (%) | 14.94 | |
| Institutions (%) | 7.40 | |
06/28 16:30 EST - globenewswire.com
Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON, June 28, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, reported today that Pyxis Oncology's Compensation Committee of the Board of Directors granted restricted stock units with respect to an aggregate of 89,530 shares of Pyxis Oncology's common stock and stock options to purchase an aggregate of 111,913 shares of Pyxis Oncology's common stock to five newly hired employees. The awards were granted under the Pyxis Oncology, Inc. 2022 Inducement Plan with a grant date of June 28, 2024, as an inducement material to the new employee entering employment with Pyxis Oncology, in accordance with Nasdaq Listing Rule 5635(c)(4).
Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON, June 28, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, reported today that Pyxis Oncology's Compensation Committee of the Board of Directors granted restricted stock units with respect to an aggregate of 89,530 shares of Pyxis Oncology's common stock and stock options to purchase an aggregate of 111,913 shares of Pyxis Oncology's common stock to five newly hired employees. The awards were granted under the Pyxis Oncology, Inc. 2022 Inducement Plan with a grant date of June 28, 2024, as an inducement material to the new employee entering employment with Pyxis Oncology, in accordance with Nasdaq Listing Rule 5635(c)(4).
06/10 07:30 EST - globenewswire.com
Pyxis Oncology Expands Board of Directors with Appointment of Michael A. Metzger
BOSTON, June 10, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: “PYXS”), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, today announced the appointment of Michael A. Metzger to its Board of Directors, effective June 10, 2024. Mr. Metzger has over 25 years of experience in the biopharmaceutical sector, currently serving as Chief Executive Officer and as a member of the Board of Directors of Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX) since 2015.
Pyxis Oncology Expands Board of Directors with Appointment of Michael A. Metzger
BOSTON, June 10, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: “PYXS”), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, today announced the appointment of Michael A. Metzger to its Board of Directors, effective June 10, 2024. Mr. Metzger has over 25 years of experience in the biopharmaceutical sector, currently serving as Chief Executive Officer and as a member of the Board of Directors of Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX) since 2015.
05/30 07:30 EST - globenewswire.com
Pyxis Oncology to Participate in a Fireside Chat at the Jefferies Global Healthcare Conference
BOSTON, May 30, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, announced today that Lara S. Sullivan, M.D., President and Chief Executive Officer, will participate in a fireside chat on Thursday, June 6, 2024 at 9:00 AM Eastern Time at the Jefferies Global Healthcare Conference in New York City, where members of management will also host investor one-on-one meetings.
Pyxis Oncology to Participate in a Fireside Chat at the Jefferies Global Healthcare Conference
BOSTON, May 30, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, announced today that Lara S. Sullivan, M.D., President and Chief Executive Officer, will participate in a fireside chat on Thursday, June 6, 2024 at 9:00 AM Eastern Time at the Jefferies Global Healthcare Conference in New York City, where members of management will also host investor one-on-one meetings.
05/20 01:06 EST - https://www.defenseworld.net
Q2 2024 EPS Estimates for Pyxis Oncology, Inc. (NASDAQ:PYXS) Decreased by Analyst
Pyxis Oncology, Inc. (NASDAQ:PYXS – Free Report) – Investment analysts at HC Wainwright lowered their Q2 2024 earnings estimates for shares of Pyxis Oncology in a research note issued on Thursday, May 16th. HC Wainwright analyst S. Ramakanth now forecasts that the company will earn ($0.27) per share for the quarter, down from their previous estimate of ($0.12). HC Wainwright currently has a “Buy” rating and a $7.00 target price on the stock. The consensus estimate for Pyxis Oncology’s current full-year earnings is ($1.09) per share. HC Wainwright also issued estimates for Pyxis Oncology’s Q3 2024 earnings at ($0.15) EPS, Q4 2024 earnings at ($0.16) EPS, FY2024 earnings at ($0.63) EPS, Q1 2025 earnings at ($0.41) EPS, Q2 2025 earnings at ($0.36) EPS, Q3 2025 earnings at ($0.36) EPS, Q4 2025 earnings at ($0.36) EPS, FY2025 earnings at ($1.49) EPS, FY2026 earnings at ($1.27) EPS, FY2027 earnings at ($1.42) EPS and FY2028 earnings at ($0.70) EPS. A number of other research analysts have also issued reports on PYXS. Royal Bank of Canada restated an “outperform” rating and set a $7.00 price target on shares of Pyxis Oncology in a research note on Friday, March 22nd. SVB Leerink initiated coverage on shares of Pyxis Oncology in a research note on Tuesday, January 23rd. They set an “outperform” rating and a $12.00 price target on the stock. BTIG Research initiated coverage on shares of Pyxis Oncology in a research note on Friday, February 9th. They set a “buy” rating and a $8.00 price target on the stock. Leerink Partnrs restated an “outperform” rating on shares of Pyxis Oncology in a research note on Tuesday, January 23rd. Finally, Jefferies Financial Group restated a “buy” rating and set a $10.00 price target on shares of Pyxis Oncology in a research note on Tuesday, May 7th. Seven investment analysts have rated the stock with a buy rating, According to MarketBeat, the company presently has an average rating of “Buy” and an average price target of $8.80. Read Our Latest Research Report on PYXS Pyxis Oncology Stock Down 0.5 % NASDAQ:PYXS opened at $4.15 on Monday. Pyxis Oncology has a 52 week low of $1.35 and a 52 week high of $6.85. The firm has a 50 day moving average of $4.68 and a 200 day moving average of $3.54. The stock has a market capitalization of $244.39 million, a price-to-earnings ratio of -3.05 and a beta of 1.45. Pyxis Oncology (NASDAQ:PYXS – Get Free Report) last posted its earnings results on Saturday, May 11th. The company reported ($0.06) EPS for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.19. The firm had revenue of $16.15 million for the quarter, compared to analysts’ expectations of $4.25 million. Institutional Trading of Pyxis Oncology Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Decheng Capital Management III Cayman LLC acquired a new stake in Pyxis Oncology during the third quarter valued at $650,000. abrdn plc acquired a new stake in Pyxis Oncology during the fourth quarter valued at $1,275,000. Acadian Asset Management LLC acquired a new stake in Pyxis Oncology during the third quarter valued at $26,000. Commonwealth Equity Services LLC acquired a new stake in Pyxis Oncology during the third quarter valued at $26,000. Finally, Schulhoff & Co. Inc. acquired a new stake in Pyxis Oncology during the third quarter valued at $44,000. Institutional investors and hedge funds own 39.09% of the company’s stock. About Pyxis Oncology (Get Free Report) Pyxis Oncology, Inc, a clinical-stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody, which is in Phase 1 clinical trial for the treatment of solid tumors, including non-small cell lung cancer (NSCLC) without driver mutations/translocations, breast cancer, endometrial cancer, thyroid cancer, kidney cancer, cholangiocarcinoma, bladder cancer, colorectal cancer, and head and neck squamous cell carcinoma. See Also Five stocks we like better than Pyxis Oncology What Does a Stock Split Mean? MarketBeat Week in Review – 5/13 – 5/17 What does consumer price index measure? Take-Two Interactive Software Offers 2nd Chance for Investors 3 Fintech Stocks With Good 2021 Prospects Deere & Company’s Q2 Report: Strong Revenue, Cautious Outlook
Q2 2024 EPS Estimates for Pyxis Oncology, Inc. (NASDAQ:PYXS) Decreased by Analyst
Pyxis Oncology, Inc. (NASDAQ:PYXS – Free Report) – Investment analysts at HC Wainwright lowered their Q2 2024 earnings estimates for shares of Pyxis Oncology in a research note issued on Thursday, May 16th. HC Wainwright analyst S. Ramakanth now forecasts that the company will earn ($0.27) per share for the quarter, down from their previous estimate of ($0.12). HC Wainwright currently has a “Buy” rating and a $7.00 target price on the stock. The consensus estimate for Pyxis Oncology’s current full-year earnings is ($1.09) per share. HC Wainwright also issued estimates for Pyxis Oncology’s Q3 2024 earnings at ($0.15) EPS, Q4 2024 earnings at ($0.16) EPS, FY2024 earnings at ($0.63) EPS, Q1 2025 earnings at ($0.41) EPS, Q2 2025 earnings at ($0.36) EPS, Q3 2025 earnings at ($0.36) EPS, Q4 2025 earnings at ($0.36) EPS, FY2025 earnings at ($1.49) EPS, FY2026 earnings at ($1.27) EPS, FY2027 earnings at ($1.42) EPS and FY2028 earnings at ($0.70) EPS. A number of other research analysts have also issued reports on PYXS. Royal Bank of Canada restated an “outperform” rating and set a $7.00 price target on shares of Pyxis Oncology in a research note on Friday, March 22nd. SVB Leerink initiated coverage on shares of Pyxis Oncology in a research note on Tuesday, January 23rd. They set an “outperform” rating and a $12.00 price target on the stock. BTIG Research initiated coverage on shares of Pyxis Oncology in a research note on Friday, February 9th. They set a “buy” rating and a $8.00 price target on the stock. Leerink Partnrs restated an “outperform” rating on shares of Pyxis Oncology in a research note on Tuesday, January 23rd. Finally, Jefferies Financial Group restated a “buy” rating and set a $10.00 price target on shares of Pyxis Oncology in a research note on Tuesday, May 7th. Seven investment analysts have rated the stock with a buy rating, According to MarketBeat, the company presently has an average rating of “Buy” and an average price target of $8.80. Read Our Latest Research Report on PYXS Pyxis Oncology Stock Down 0.5 % NASDAQ:PYXS opened at $4.15 on Monday. Pyxis Oncology has a 52 week low of $1.35 and a 52 week high of $6.85. The firm has a 50 day moving average of $4.68 and a 200 day moving average of $3.54. The stock has a market capitalization of $244.39 million, a price-to-earnings ratio of -3.05 and a beta of 1.45. Pyxis Oncology (NASDAQ:PYXS – Get Free Report) last posted its earnings results on Saturday, May 11th. The company reported ($0.06) EPS for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.19. The firm had revenue of $16.15 million for the quarter, compared to analysts’ expectations of $4.25 million. Institutional Trading of Pyxis Oncology Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Decheng Capital Management III Cayman LLC acquired a new stake in Pyxis Oncology during the third quarter valued at $650,000. abrdn plc acquired a new stake in Pyxis Oncology during the fourth quarter valued at $1,275,000. Acadian Asset Management LLC acquired a new stake in Pyxis Oncology during the third quarter valued at $26,000. Commonwealth Equity Services LLC acquired a new stake in Pyxis Oncology during the third quarter valued at $26,000. Finally, Schulhoff & Co. Inc. acquired a new stake in Pyxis Oncology during the third quarter valued at $44,000. Institutional investors and hedge funds own 39.09% of the company’s stock. About Pyxis Oncology (Get Free Report) Pyxis Oncology, Inc, a clinical-stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody, which is in Phase 1 clinical trial for the treatment of solid tumors, including non-small cell lung cancer (NSCLC) without driver mutations/translocations, breast cancer, endometrial cancer, thyroid cancer, kidney cancer, cholangiocarcinoma, bladder cancer, colorectal cancer, and head and neck squamous cell carcinoma. See Also Five stocks we like better than Pyxis Oncology What Does a Stock Split Mean? MarketBeat Week in Review – 5/13 – 5/17 What does consumer price index measure? Take-Two Interactive Software Offers 2nd Chance for Investors 3 Fintech Stocks With Good 2021 Prospects Deere & Company’s Q2 Report: Strong Revenue, Cautious Outlook
05/14 09:41 EST - zacks.com
Pyxis Oncology, Inc. (PYXS) Reports Q1 Loss, Tops Revenue Estimates
Pyxis Oncology, Inc. (PYXS) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to loss of $0.54 per share a year ago.
Pyxis Oncology, Inc. (PYXS) Reports Q1 Loss, Tops Revenue Estimates
Pyxis Oncology, Inc. (PYXS) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to loss of $0.54 per share a year ago.
05/14 07:30 EST - globenewswire.com
Pyxis Oncology Provides Corporate Update and Reports Financial Results for First Quarter 2024
PYX-201 Phase 1 trial clinical readout on track for fall of 2024 Executive Leadership Team expanded with the appointment of Stephen Worsley as Senior Vice President, Chief Business Officer PYX-106 Phase 1 trial clinical readout on track for 2H 2024 Expected cash runway into 2H 2026 BOSTON, May 14, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, today reported financial results for the first quarter ended March 31, 2024, and provided a corporate update. PYX-201, a first-in-concept tumor stroma targeting antibody-drug conjugate (ADC) against the stromal Extradomain-B Fibronectin (EDB+FN) target, has dosed 42 patients in 8 cohorts since initiating the Phase 1 trial in March 2023 with continued enthusiasm for this agent by global investigators.
Pyxis Oncology Provides Corporate Update and Reports Financial Results for First Quarter 2024
PYX-201 Phase 1 trial clinical readout on track for fall of 2024 Executive Leadership Team expanded with the appointment of Stephen Worsley as Senior Vice President, Chief Business Officer PYX-106 Phase 1 trial clinical readout on track for 2H 2024 Expected cash runway into 2H 2026 BOSTON, May 14, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, today reported financial results for the first quarter ended March 31, 2024, and provided a corporate update. PYX-201, a first-in-concept tumor stroma targeting antibody-drug conjugate (ADC) against the stromal Extradomain-B Fibronectin (EDB+FN) target, has dosed 42 patients in 8 cohorts since initiating the Phase 1 trial in March 2023 with continued enthusiasm for this agent by global investigators.
05/09 07:30 EST - globenewswire.com
Pyxis Oncology to Present at the RBC Capital Markets Global Healthcare Conference
BOSTON, May 09, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, announced today that Lara S. Sullivan, M.D., President and Chief Executive Officer, will participate in a fireside chat on Tuesday, May 14, 2024 at 3:05 PM ET at the RBC Capital Markets Global Healthcare Conference, where members of management will also host investor one-on-one meetings.
Pyxis Oncology to Present at the RBC Capital Markets Global Healthcare Conference
BOSTON, May 09, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, announced today that Lara S. Sullivan, M.D., President and Chief Executive Officer, will participate in a fireside chat on Tuesday, May 14, 2024 at 3:05 PM ET at the RBC Capital Markets Global Healthcare Conference, where members of management will also host investor one-on-one meetings.
04/12 10:56 EST - zacks.com
Does Pyxis Oncology (PYXS) Have the Potential to Rally 61.29% as Wall Street Analysts Expect?
The average of price targets set by Wall Street analysts indicates a potential upside of 61.3% in Pyxis Oncology (PYXS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Does Pyxis Oncology (PYXS) Have the Potential to Rally 61.29% as Wall Street Analysts Expect?
The average of price targets set by Wall Street analysts indicates a potential upside of 61.3% in Pyxis Oncology (PYXS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
03/27 13:07 EST - investorplace.com
3 Biotech Stocks to Buy on the Dip: March 2024
One of the best dip-buying opportunities in biotech stocks to buy was in Viking Therapeutics (NASDAQ: VKTX ). After hitting a high of $99.41, VKTX dipped back to about $60.30.
3 Biotech Stocks to Buy on the Dip: March 2024
One of the best dip-buying opportunities in biotech stocks to buy was in Viking Therapeutics (NASDAQ: VKTX ). After hitting a high of $99.41, VKTX dipped back to about $60.30.
03/27 07:30 EST - globenewswire.com
Pyxis Oncology Obtains $8 Million Payment for the Sale of Royalty Rights
Non-dilutive funding to support development of first-in-concept lead Antibody-Drug Conjugate (ADC) asset, PYX-201 Pyxis Oncology retains rights to three other antibodies in development by Apexigen's licensees discovered through the APXiMAB platform BOSTON, March 27, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, announced today that it has completed the sale of its rights to royalties from the commercialization of Beovu ® (brolucizumab-dbll) and another asset to Novartis for a one-time cash payment of $8 million. As part of Pyxis Oncology's acquisition of Apexigen, Inc., in August 2023, the Company gained rights to royalties on Beovu and another asset discovered using APXiMAB, Apexigen's proprietary antibody discovery platform.
Pyxis Oncology Obtains $8 Million Payment for the Sale of Royalty Rights
Non-dilutive funding to support development of first-in-concept lead Antibody-Drug Conjugate (ADC) asset, PYX-201 Pyxis Oncology retains rights to three other antibodies in development by Apexigen's licensees discovered through the APXiMAB platform BOSTON, March 27, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, announced today that it has completed the sale of its rights to royalties from the commercialization of Beovu ® (brolucizumab-dbll) and another asset to Novartis for a one-time cash payment of $8 million. As part of Pyxis Oncology's acquisition of Apexigen, Inc., in August 2023, the Company gained rights to royalties on Beovu and another asset discovered using APXiMAB, Apexigen's proprietary antibody discovery platform.
03/26 13:01 EST - zacks.com
All You Need to Know About Pyxis Oncology (PYXS) Rating Upgrade to Buy
Pyxis Oncology (PYXS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
All You Need to Know About Pyxis Oncology (PYXS) Rating Upgrade to Buy
Pyxis Oncology (PYXS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
03/21 07:30 EST - globenewswire.com
Pyxis Oncology Provides Corporate Update and Reports Financial Results for Fourth Quarter and Full Year 2023
PYX-201 Phase 1 Part 1 trial progressing with initial data expected in the fall of 2024 PYX-106 Phase 1 trial progressing with initial data expected 2H 2024 Completed $50 million private placement Expected cash runway into 2H 2026 BOSTON, March 21, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, today reported financial results for the year and quarter ended December 31, 2023, and provided a corporate update. PYX-201, a first-in-concept tumor stroma targeting antibody-drug conjugate (ADC) against the stromal Extradomain-B Fibronectin (EDB+FN) target, has dosed 37 patients in 6 cohorts since initiating the Phase 1 trial in March 2023.
Pyxis Oncology Provides Corporate Update and Reports Financial Results for Fourth Quarter and Full Year 2023
PYX-201 Phase 1 Part 1 trial progressing with initial data expected in the fall of 2024 PYX-106 Phase 1 trial progressing with initial data expected 2H 2024 Completed $50 million private placement Expected cash runway into 2H 2026 BOSTON, March 21, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, today reported financial results for the year and quarter ended December 31, 2023, and provided a corporate update. PYX-201, a first-in-concept tumor stroma targeting antibody-drug conjugate (ADC) against the stromal Extradomain-B Fibronectin (EDB+FN) target, has dosed 37 patients in 6 cohorts since initiating the Phase 1 trial in March 2023.
03/19 14:58 EST - investorplace.com
From Six Figures to Seven: 3 Biotech Stocks Set to Make Millionaires
Given the current risk-on sentiment, it is perhaps an ideal time for investors to scoop up some of the top biotech stocks. The stock market is booming, and with investors looking to take on more risk, a potential surge in biotech stocks seems likely.
From Six Figures to Seven: 3 Biotech Stocks Set to Make Millionaires
Given the current risk-on sentiment, it is perhaps an ideal time for investors to scoop up some of the top biotech stocks. The stock market is booming, and with investors looking to take on more risk, a potential surge in biotech stocks seems likely.
03/13 08:00 EST - globenewswire.com
Pyxis Oncology Expands Board of Directors with Appointment of Santhosh Palani, Ph.D., CFA
BOSTON, March 13, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: “PYXS”), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, today announced the appointment of Santhosh Palani, Ph.D., CFA, to its board of directors, effective March 12, 2024.
Pyxis Oncology Expands Board of Directors with Appointment of Santhosh Palani, Ph.D., CFA
BOSTON, March 13, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: “PYXS”), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, today announced the appointment of Santhosh Palani, Ph.D., CFA, to its board of directors, effective March 12, 2024.
03/07 16:30 EST - globenewswire.com
Pyxis Oncology to Present at Leerink Global Biopharma Conference 2024
BOSTON, March 07, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, announced today that Lara S. Sullivan, M.D., President and Chief Executive Officer, will participate in a fireside chat on Wednesday, March 13, 2024 at 8:40 AM EST at the Leerink Partners Global Biopharma Conference, Miami Beach, Florida, where members of management will also host investor one-on-one meetings.
Pyxis Oncology to Present at Leerink Global Biopharma Conference 2024
BOSTON, March 07, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, announced today that Lara S. Sullivan, M.D., President and Chief Executive Officer, will participate in a fireside chat on Wednesday, March 13, 2024 at 8:40 AM EST at the Leerink Partners Global Biopharma Conference, Miami Beach, Florida, where members of management will also host investor one-on-one meetings.
03/05 16:45 EST - globenewswire.com
Pyxis Oncology to Present New PYX-201, PYX-106 and PYX-102 Preclinical Data at AACR Annual Meeting
PYX-201, an EDB+FN-specific tumor stroma-targeting ADC, demonstrates potent anti-tumor efficacy across multiple human cancers in PDX tumor models
Pyxis Oncology to Present New PYX-201, PYX-106 and PYX-102 Preclinical Data at AACR Annual Meeting
PYX-201, an EDB+FN-specific tumor stroma-targeting ADC, demonstrates potent anti-tumor efficacy across multiple human cancers in PDX tumor models
02/22 18:00 EST - investorplace.com
3 Biotech Stocks to Turn $10,000 Into $1 Million: February 2024
With new innovation, high demand for better treatment, pharmaceutical companies strengthening pipelines and a resurgence of mergers and acquisitions, biotech stocks could offer some of the most explosive opportunities of the year. “What's more, big pharmaceutical companies with sizable piles of cash and the need to address patent expirations on some top-selling products later this decade will be hunting for companies with innovative drugs in development,” says Morningstar.com.
3 Biotech Stocks to Turn $10,000 Into $1 Million: February 2024
With new innovation, high demand for better treatment, pharmaceutical companies strengthening pipelines and a resurgence of mergers and acquisitions, biotech stocks could offer some of the most explosive opportunities of the year. “What's more, big pharmaceutical companies with sizable piles of cash and the need to address patent expirations on some top-selling products later this decade will be hunting for companies with innovative drugs in development,” says Morningstar.com.
11/07 16:30 EST - globenewswire.com
Pyxis Oncology Announces Initiatives to Prioritize Lead ADC Program; Reports Financial Results for Third-Quarter 2023 and Provides Corporate Update
PYX-201 (a novel first-in-concept and first-in-class tumor stroma targeting antibody-drug conjugate [ADC] product candidate) Phase 1 trial progressing with fifth dose cohort at 3.6 mg/kg ; data expected 1H 2024.
Pyxis Oncology Announces Initiatives to Prioritize Lead ADC Program; Reports Financial Results for Third-Quarter 2023 and Provides Corporate Update
PYX-201 (a novel first-in-concept and first-in-class tumor stroma targeting antibody-drug conjugate [ADC] product candidate) Phase 1 trial progressing with fifth dose cohort at 3.6 mg/kg ; data expected 1H 2024.